Frontier Pharma: Alzheimers Disease and Associated Indications Market | Increasing Technological Developments to Support Market Growth

Researchmoz added Most up-to-date research on "Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression" to its huge collection of research reports.

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1135804

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
What are the most important etiological risk factors and pathophysiological processes implicated in AD?
What is the current treatment algorithm?
How common are anxiety, depression, psychosis and insomnia in AD?

The AD pipeline is large and contains a very high proportion of first-in-class product innovation
Which molecule types and molecular targets are most prominent across AD and its associated indications?
What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
Which first-in-class targets are most promising?
How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
How does first-in-class target diversity differ by stage of development and molecular target class?

The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
Which indications attract the highest deal values?
How has deal activity fluctuated over the past decade?
Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-alzheimers-disease-and-associated-indications-exceptional-level-of-firstinclass-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression-report.html/toc

Reasons to buy

This report will allow you to -
Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
Identify leading products and key unmet needs within the market.
Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1135804

2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6

3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: https://marketreserch1.blogspot.com

This release was published on openPR.